Quantbot Technologies LP bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 71,429 shares of the company's stock, valued at approximately $1,026,000. Quantbot Technologies LP owned 0.06% of 10x Genomics at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. raised its stake in shares of 10x Genomics by 9.6% during the 4th quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock valued at $155,000 after buying an additional 943 shares during the last quarter. Blue Trust Inc. raised its position in 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after acquiring an additional 1,299 shares in the last quarter. Sound Income Strategies LLC raised its position in 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock valued at $48,000 after acquiring an additional 1,330 shares in the last quarter. Signaturefd LLC lifted its holdings in 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after acquiring an additional 1,452 shares during the period. Finally, KBC Group NV boosted its position in 10x Genomics by 57.3% in the 4th quarter. KBC Group NV now owns 5,072 shares of the company's stock worth $73,000 after purchasing an additional 1,847 shares in the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several analysts recently commented on the stock. UBS Group dropped their price target on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Citigroup reduced their target price on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, March 22nd. JPMorgan Chase & Co. lowered their target price on 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Finally, Barclays cut their target price on 10x Genomics from $19.00 to $18.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $20.21.
Read Our Latest Stock Report on 10x Genomics
Insiders Place Their Bets
In other 10x Genomics news, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. The trade was a 1.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alan Mateo acquired 40,000 shares of the company's stock in a transaction on Friday, February 21st. The stock was purchased at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the transaction, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their position. The disclosure for this purchase can be found here. Insiders own 10.03% of the company's stock.
10x Genomics Trading Down 2.7 %
10x Genomics stock traded down $0.25 during trading on Friday, hitting $9.16. The company had a trading volume of 2,665,243 shares, compared to its average volume of 2,075,825. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -6.03 and a beta of 1.93. 10x Genomics, Inc. has a 1-year low of $8.92 and a 1-year high of $37.86. The company's 50 day simple moving average is $12.12 and its 200-day simple moving average is $15.13.
10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current fiscal year.
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
See Also
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
